Novartis | NVS - Operating Expenses

Stock Price
145.47
Daily Change
-2.06 -1.40%
Monthly
-3.46%
Yearly
29.62%
Q2 Forecast
149.02

Novartis reported $9.8B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bausch Health Companies USD 2.08B 113M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Canopy Growth CAD 87.2M 6.22M Dec/2025
Corcept Therapeutics USD 197.64M 219K Dec/2025
Drreddys Laboratories INR 72.94B 4.33B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
J&J USD 17.44B 1.53B Mar/2026
Merck USD 10.16B 558M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Pacira USD 193.68M 27.32M Dec/2025
Perrigo USD 1.03B 75.3M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Phibro Animal Health USD 332.36M 20.68M Dec/2025
Prestige Brands USD 200.95M 6.51M Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
Sanofi EUR 10.71B 1.32B Dec/2025
Supernus Pharmaceuticals USD 197.75M 54.54M Dec/2025
Zoetis USD 1.55B 3.85B Dec/2025